Sign In
Buy CCXI
$10.24
+0.0150 (+0.147%)
At Close: Jun 03, 2026
Chemocentryx Stock Needs To Hold At Support Or It May Slide Lower
01:10pm, Thursday, 30'th Sep 2021
ChemoCentryx Inc (NASDAQ: CCXI) shares are trading lower Thursday, although there looks to be no company-evident news to explain the jump in share price. The stock was trending throughout the day on
Why Are ChemoCentryx's Shares Trading Higher Today?
03:54pm, Monday, 27'th Sep 2021
ChemoCentryx Inc's (NASDAQ: CCXI) partner Kissei Pharmaceutical Co Ltd has received approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW) to market Tavneos (avacopan). Avacopan
ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated Vasculitis
08:30am, Monday, 27'th Sep 2021
Approved for use in Japan in patients with microscopic polyangiitis and granulomatosis with polyangiitis Approved for use in Japan in patients with microscopic polyangiitis and granulomatosis with pol
2 Growth Stocks That Could Take Off Before the End of the Year
09:11am, Thursday, 16'th Sep 2021
They've been struggling thus far in 2021, but things could turn around quickly for these companies.
Is the Options Market Predicting a Spike in ChemoCentryx (CCXI) Stock?
11:28am, Wednesday, 15'th Sep 2021
Investors need to pay close attention to ChemoCentryx (CCXI) stock based on the movements in the options market lately.
ChemoCentryx (CCXI) Up 10.5% Since Last Earnings Report: Can It Continue?
01:16pm, Wednesday, 08'th Sep 2021
ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock?
ChemoCentryx to Participate in Two Upcoming Investor Conferences
08:30am, Thursday, 02'nd Sep 2021
SAN CARLOS, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two
ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends
02:24pm, Tuesday, 24'th Aug 2021
Most expected CCXI to have achieved regulatory approval for avacopan to treat ANCA-Associated Vasculitis on July 7, 2021.
Are Options Traders Betting on a Big Move in ChemoCentryx (CCXI) Stock?
11:00am, Wednesday, 11'th Aug 2021
Investors need to pay close attention to ChemoCentryx (CCXI) stock based on the movements in the options market lately.
ChemoCentryx (CCXI) Q2 Loss Wider Than Expected, Sales Down
12:24pm, Tuesday, 10'th Aug 2021
ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the second quarter and misses on sales.
ChemoCentryx, Inc. (CCXI) CEO Tom Schall on Q2 2021 Results - Earnings Call Transcript
11:03pm, Monday, 09'th Aug 2021
ChemoCentryx, Inc. (CCXI) CEO Tom Schall on Q2 2021 Results - Earnings Call Transcript
ChemoCentryx: Q2 Earnings Insights
05:36pm, Monday, 09'th Aug 2021
Shares of ChemoCentryx (NASDAQ:CCXI) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 293.10% year over year to ($0.56), which missed the e
ChemoCentryx to Participate in the Canaccord Genuity 41st Annual Growth Conference
08:30am, Wednesday, 04'th Aug 2021
SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fir
Analysts Estimate ChemoCentryx (CCXI) to Report a Decline in Earnings: What to Look Out for
04:46pm, Monday, 02'nd Aug 2021
ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChemoCentryx to Hold Second Quarter 2021 Financial Results Conference Call on Monday, August 9, 2021
08:30am, Monday, 02'nd Aug 2021
MOUNTAIN VIEW, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2021 financial results will be released after market clos
